Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product

Immunogenetics

Volumn 51, Issue 2, 2000, Pages 99-107

  Oka, Yoshihiro ^a   Elisseeva, Olga A ^a   Tsuboi, Akihiro ^a   Ogawa, Hiroyasu ^a   Tamaki, Hiroya ^a   Li, Hanfen ^a   Oji, Yusuke ^a   Kim, Eui Ho ^a   Soma, Toshihiro ^a   Asada, Momotaro ^a   Ueda, Kazuyuki ^a   Maruya, Etsuko ^b   Saji, Hiroh ^b   Kishimoto, Tadamitsu ^c   Udaka, Keiko ^d   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b JAPANESE RED CROSS SOCIETY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Cytotoxic T lymphocytes; Immunotherapy; Tumor specific antigen; Wilms' tumor gene; WT1

Indexed keywords

CD8 ANTIGEN; GENE PRODUCT; HLA A2 ANTIGEN; PEPTIDE; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN PRESENTATION; ARTICLE; BLAST CELL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOBLASTOID CELL; MONONUCLEAR CELL; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN BINDING; SOLID TUMOR; VACCINATION;

EID: 0034112824     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002510050018     Document Type: Article

References (80)

1. Baird PN, Simmons PJ (1997) Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25: 312-320
2. Bertholet S, Iggo R, Corradin G (1997) Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur J Immunol 27:798-801
3. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Fiaccadorl F, Ferrari C (1994) Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407-410
4. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587-3592
5. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L (1994) The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 8:2138-2143
6. Brown SL, Miller RA, Levy R (1989) Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 16:199-210
7. Burkly LC, Lo D, Kanagawa O, Brinster RL, Flavell RA (1989) T-cell tolerance by clonal anergy in transgenic mice with non-lymphoid expression of MHC class II I-E. Nature 342:564-566
8. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C, Housman DE (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520
9. BCR-ABL protein. Proc Natl Acad Sci USA 89:1468-1472
10. Corundolo V, Alexander J, Anderson JK, Lamb C, Cresswell P, McMichael A, Gotch F, Townsend A (1990) Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 345:449-452
11. Coussens L, Yang-Feng TL, Chen YLE, Gray A, McGrath J, Seeburg PH, Liberman TA, Schlessinger J, Francke U, Levinson A, Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Sience 230:1132-1139
12. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719
13. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Gioner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, MA Cheever (1994) Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20
14. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA (1996) Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J Immunol 156:3151-3158
15. Drummong IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher III FJ (1992) Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257:674-678
16. Fisk B, Blevins TL, Wharton JT, Loannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protoon-cogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117
17. + T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol 28:305-316
18. Gashler AL, Bonthron DT, Madden SL, Rauscher FJ III, Collins T, Sukhatme VP (1992) Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA 89:10984-10988
19. Gessler M, Poustka A, Cavenee W, Nevel RL, Orkin SH, Bruns GAP (1990) Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774-778
20. + T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 72:784-790
21. Gusterson B, Gelber R, Goldhirsch A, Price K, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam C, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville A, Bürkt K, Castiglione M, Collins J, Lindtner J, Senn H-J (1992) Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056
22. Harrington MA, Konicek B, Song A, Xia X-L, Fredericks WJ, Rauscher FJ III (1993) Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 268:21271-21275
23. Houbiers JGA, Nijman HW, Burg SH van der, Drijfhout JW, Kenemans P, Velde CJH van de, Brand A, Momburg F, Kast WM, Melief CJM (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072-2077
24. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi H, Ishidate T, Akiyama T, Kishimoto T (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071-3079
25. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, Oji Y, Tamaki H, Kyo T, Dohy H, Hiraoka A, Masaoka T, Kishimoto T, Sugiyama H (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88:2267-2278
26. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Kishimoto T, Sugiyama H (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405-1412
27. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Akiyama T, Kishimoto T, Sugiyama H (1998) Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91:2969-2976
28. Jung S, Schluesener HJ (1991) Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173:273-276
29. Kawai S, Maekawajiri S, Yamane A (1993) A simple method of amplified DNA with immobilized probes on microtiter wells. Anal Biochem 209:63-69
30. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462
31. + helper T cells, and reversal of tolerance through introduction of third-party helper T cells. J Exp Med 172:105-113
32. Kitamura T, Tange T, Terasawa T, Chiba S, Kumaki T, Miyagawa K, Piao Y-F, Miyazono K, Urabe A, Takaku F (1989) Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 140:323-334
33. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Elsenbach L (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67-71
34. Maruya E, Ishikawa Y, Lin L, Tokunaga K, Kimura A, Saji H (1996) Allele typing of HLA-A10 group by nested-PCR-low ionic strength single stranded conformation polymorphism and novel A26 allele (A26KY, A*2605). Hum Immunol 50:140-147
35. + progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 25:945-950
36. Melief CJM, Kast WM (1995) T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145:167-177
37. Menke AL, Van der Eb A, Jochemsen AG (1998) The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? Int Rev Cytol 181:151-212
38. Menssen HD, Renkl H-J, Rodeck U, Maurer J, Notier M, Schwartz S, Reinhardt R, Thiel E (1995) Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9:1060-1067
39. + hematopoietic progenitors during fetal development and early clonogenic growth. Blood 89:3486-3487
40. Minowada J, Ohnuma T, Moore GE (1972) Rosette forming human lymphoid cell line. 1. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 49:891-895
41. Miwa H, Beran M, Saunders GF (1992) Expression of the Wilms tumor gene (WT1) in human leukemias. Leukemia 6:405-409
42. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I (1993) Expression of the candidate Wilms tumor gene, WT1, in human leukemia cells. Leukemia 7:970-977
43. Molldrem J, Dermine S, Parker K, Jiang YZ, Marrovdis D, Hensel N, Fukushima P, Barrett AJ (1996) Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88:2450-2457
44. Morrison J, Elvin J, Latron F, Gotch F, Moots R, Strominger JL, McMichael A (1992) Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur J Immunol 22:903-907
45. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM (1993) Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758-761
46. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Furukawa K, Kanematsu T, Shiku H (1997) Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159:1336-1343
47. Nijman HW, Van der Burg SH, Vierboom MPM, Houbiers JGA, Kast WM, Melief CJM (1994) P53, a potential target for tumor-directed T cells. Immunol Lett 40:171-178
48. + T cells. Proc Natl Acad Sci USA 91:3171-3175
49. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, Kishimoto T, Sugiyama H (1999) Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90:194-204
50. Parham P, Alpert BN, Orr HT, Strominger JL (1977) Carbohydrate moiety of HLA antigens. J Biol Chem 252:7555-7567
51. Peace DJ, Chen W, Nelson H, Cheever MA (1991) T cell recognition of transforming proteins encoded by mutated ras protooncogenes. J Immunol 146:2059-2065
52. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436
53. Rammensee H-G, Friede T, Stevanović S (1995) MHC ligands and pepetide motifs: first listing. Immunogenetics 41:178-228
54. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJM, Kast WM (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934-5943
55. Ritz J (1994) Tumor immunitiy: will new keys unlock the door. J Clin Oncol 12:237-238
56. Salter RD, Cresswell P (1986) Impaired assembly and transport of HLA-A and -B antigens in a mutant TXB cell hybrid. EMBO J 5:943-949
57. Schild H-J, Rötzschke O, Kaibacher H, Rammensee H-G (1990) Limit of T cell tolerance to self proteins by peptide presentation. Science 247:1587-1589
58. Semba K, Kamata N, Toyoshima K, Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2 is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501
59. Servetnick N, Shizuru J, Liggitt D, Martin L, McIntyre B, Gregory A, Parslow T, Stewart T (1990) Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ. Nature 346:844-847
60. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
61. Soldevila G, Geiger T, Flavell RA (1995) Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen. J Immunol 155:5590-5600
62. Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyake S, Oka Y, Oji Y, Tatekawa T, Tsuboi A, Tagawa S, Kitani T, Miwa H, Kita K, Aozasa K, Kishimoto T, Sugiyama H (1996) Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood 88:4396-41398
63. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92:11993-11997
64. Traversari C, Van der Buggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytotoxic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453-1457
65. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc Natl Acad Sci USA 88:11276-11280
66. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y, Kim EH, Soma T, Tatekawa T, Kawakami M, Kishimoto T, Sugiyama H (1999) Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 23:499-505
67. Udaka K, Wiesmüller K-H, Kienle S, Jung G, Waiden P (1995) Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocytes epitopes with complex peptide libraries. J Exp Med 181:2097-2108
68. Van der Bruggen P, Traversari PC, Chomez P, Lurquin C, De Plaen E, Eynde B van den, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254:1643-1647
69. Van der Bruggen P, Szikora J-P, Boël P, Wildmann C, Somville M, Sensi M, Boon T (1994a) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 24:2134-2140
70. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Travesari C, Townsend A, Boon T (1994b) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
71. Vierboom MPM, Nijman HW, Offringa R, Voort EIH van der, Hall T van, Broek L van den, Fleuren GJ, Kenemans P, Kast WM, Melief CJM (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186:695-704
72. Visseren MJW, Elsas A van, Voort EIH van der, Ressing ME, Kast WM, Schrier PI, Melief CJM (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 154:3991-3998
73. Webb S, Morris C, Sprent J (1990) Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63:1249-1256
74. Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher FJ III, Sens DA, Garvin AJ, LeRoith D, Roberts CT Jr (1993) Increased expression of the insulin-like growth factor I receptor gene, IGFIR, in Wilms tumor is correlated with modulation of IGFIR promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 90:5828-5832
75. Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde K-H, Boon T (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytotolytic T lymphocytes. Eur J Immunol 24:759-764
76. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T, Kishimoto T (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87:2878-2884
77. + cytotoxic T-cells. Cancer Res 53:3257-3261
78. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vemant J-P, Lemonnier FA, Leblond V, Langlade-Demoyen P (1998a) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101:2290-2296
79. Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P (1998b) Cytotoxic T cell response against the chimeric ETV6-AML1 childhood acute lymphoblastic leukemia. J Clin Invest 102:455-462
80. Zweerink HJ, Gammon MC, Utz R, Sauma SY, Harrer T, Hawkins JC, Johnson RP, Sirotina A, Hermes JD, Walker BD, Biddison WE (1993) Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol 150:1763-1771